Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : LVG00111Z
Storage : -80℃ Shipping : Frozen on dry ice
Titer: Size:
| Cat. No. | LVG00111Z |
| Description | Lentivirus particles containing firefly luciferase reporter gene under the control of a minimal promoter (TATA-box only). |
| Titer | Varies lot by lot, for example, ≥1*10^7 TU/mL, ≥1*10^8 TU/mL, ≥1*10^9 TU/mL etc. |
| Size | Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Summary | Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots. |
| Mycoplasma | Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination. |
| Purity | Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards. |
| Sterility | The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities. |
| Proviral Identity Confirmation | All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert. |
The negative control FLuc reporter lentivirus is a ready-to-use, replication-deficient lentiviral vector designed to establish a true background baseline for luciferase assays. It encodes the firefly luciferase (FLuc) reporter gene, controlled by a minimal promoter containing only a TATA box, ensuring extremely low basal transcription levels in the absence of upstream regulatory elements. This design minimizes non-specific promoter activity and produces consistently low background signals across various cell types, making it an ideal negative control for comparison with experimental constructs containing enhancers, promoters, or transcription factor binding sites. Built on a modern lentiviral backbone, this vector supports stable genomic integration, enabling persistent signal characteristics during long-term culture in both dividing and non-dividing cells.
This negative control lentivirus is suitable for all luciferase assays requiring precise determination of baseline luminescence levels. It provides a crucial reference for quantifying promoter leakage, establishing detection thresholds, and assessing dynamic range in gene regulation, pathway activation, and enhancer function studies. In high-throughput screening, it helps determine the lower limit of detection, supports the calculation of performance metrics, and flags compounds or conditions that falsely elevate background signals. In genomic engineering and functional genomics research, it provides a reliable control for reporter gene constructs used in CRISPRa/i, transcription factor overexpression, or epigenetic regulation, ensuring that any observed luminescence is attributable to the specific regulatory input and not the activity of the vector itself. In preclinical imaging studies, it can serve as a control for in vitro or ex vivo assays to assess non-specific substrate oxidation and instrument sensitivity, aiding in standardization across different cell lines and experimental batches.
The failure of the spinal cord to regenerate after injury is primarily due to growth inhibition caused by the injury-induced inflammatory response, which cannot be alleviated, leading to secondary injury and cell death. Alleviating the inflammatory response by attenuating the inflammatory response and promoting a shift in macrophages toward an anti-inflammatory phenotype, thereby preventing inhibition, is essential to create a microenvironment that favors growth. Inducing the expression of anti-inflammatory factors through viral gene delivery has the potential to modify the host inflammatory response through local delivery. Here, it was shown that bridge implantation reduced antigen-presenting cell infiltration at day 7, while the addition of lentivirus to the bridge induced a transient increase in spinal cord neutrophils at day 7 and macrophages at day 14. Delivery of lentivirus encoding IL-10, an anti-inflammatory factor that inhibits immune cell activation and polarizes the macrophage population toward an anti-inflammatory phenotype, reduced neutrophil infiltration at days 7 and 28. Although the IL-10 lentivirus did not affect macrophage numbers, it skewed the macrophage population toward an anti-inflammatory M2 phenotype and altered macrophage morphology. Furthermore, IL-10 delivery improved motor function, suggesting reduced secondary injury and increased protection. These results suggest that local expression of anti-inflammatory factors such as IL-10 can modulate the inflammatory response after SCI and may be a key component of a combinatorial approach targeting multiple barriers to regeneration and functional recovery.
Axon number and myelination were quantified at day 28 to assess whether IL-10 overexpression was detrimental, as has been reported in the peripheral nervous system. At 28 days post SCI, myelinated (NF200+/MBP+) and unmyelinated (NF200+/MBP-) axons were seen throughout the bridges in animals that received no lentivirus, FLUC-encoding control lentivirus, or IL-10-encoding lentivirus (Figure 1A-D). NF200+ axons were often observed in bundles, as previously reported for multichannel PLG bridges. Empty bridges had approximately 800 neurites/mm2 and both lentiviral conditions had approximately 1100 neurites/mm2. While the data suggest that the density of regenerating axons tends to increase with lentiviral delivery, these differences were not statistically significant. Similarly, the percentage of axons that were myelinated (22-34%) or that were derived from Schwann cells (15-35%) did not vary between conditions (Figure 1E).
Figure 1. Myelinated axons 4 weeks after injury. (Margul D J, et al., 2016)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The negative control FLuc lentivirus worked flawlessly in our dual-luciferase assays. No background noise, just clean results every time. Highly recommended!
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.